Publications in collaboration with researchers from Hospital Universitario 12 de Octubre (30)

2020

  1. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

2018

  1. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

    Annals of Oncology, Vol. 29, pp. ix24

2009

  1. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer

    Breast Journal

2006

  1. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902

  2. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support

    Journal of Clinical Oncology, Vol. 24, Núm. 22, pp. 3611-3618

  3. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 889-895

2005

  1. Cancer-related anemia: Pathogenesis, prevalence and treatment

    Oncology

  2. It is not time to stop progesterone receptor testing in breast cancer [16]

    Journal of Clinical Oncology

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

  2. Initially Metastatic Breast Carcinoma Has a Distinct Disease Pattern but an Equivalent Outcome Compared with Recurrent Metastatic Breast Carcinoma

    Cancer, Vol. 100, Núm. 9, pp. 1833-1842

2003

  1. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer

    Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291

  2. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy

    Leukemia, Vol. 17, Núm. 2, pp. 437-441

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743

2001

  1. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial

    Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38

  2. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: A phase I trial

    Bone Marrow Transplantation, Vol. 27, Núm. 2, pp. 117-123

  3. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: A Phase II multicentric trial

    Cancer, Vol. 92, Núm. 10, pp. 2508-2516

  4. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide

    Leukemia, Vol. 15, Núm. 3, pp. 430-439

2000

  1. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: Results of a randomized clinical trial

    Journal of Clinical Oncology, Vol. 18, Núm. 10, pp. 2126-2134

1999

  1. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial

    Cancer, Vol. 85, Núm. 1, pp. 213-219